Hepatitis C Patients with Progress of Disease Severity: Biochemical and Immunological studies
DOI:
https://doi.org/10.48165/Keywords:
Chronic hepatitis C , liver function , immune systemAbstract
Hepatitis C infection has become epidemic with a rapid increase in the number of patients. Hepatitis C has some streaking among which are; most cases don't correlate with the histological of the hepatic biopsies of these patients. The present study aims at investigating some biochemical and immunological aspects among patients varying in degree of disease severity. The study includes 112 subjects; 24 healthy control and 88 CHC patients, grouped as follows: Group I: (control group), Group II: compensated chronic liver disease (without cirrhosis), Group III: decompensated with liver cirrhosis and Group IV: hepatocellular failure; end stage liver. Results of the present study showed that serum aspartate and alanine transaminases (AST & ALT), gamma glutamyl transferase (GGT), alkaline phosphatase (ALP) activities, total and direct bilirubin, globulin, AST/platelet ratio index (APRI), globulin/platelet ratio, tumor necrosis factor-α (TNF-a), interferon-g (IFN-g), interleukins (lL-2 & IL-4), immunoglobulins (lgA, IgM and IgG), concentrations were increased significantly in all CHC patients groups while, albumin, albumin/globulin ratio (AIG ratio), platelets count, multivariate disriminant analysis (MDA) (based on 4 variables, AST/ALT,platelets, ALP & albumin), were decreased significantly in all CHC patients groups compared to the control group. AST/ALT ratio increased in all groupsexcept GroupII.CD4+%wasignificantly low in Group III and Group IV, while CD8+% decreased significantly in Group II & Group IV.It was concluded that biochemical tests in combination with each other could diagnose serious pathological disorders. Furthermore, immune parameters possibly play a role in the degradation process of the liver. Although, immune system components contribute to the liver injury, they maintain low viral load in advanced stages.
References
Armstrong, W.D. and Carr, C.W. (1964): Physiological Chemistry: Laboratory Directions. 3rd ed., pp. 75. Burges Publishing Co., Minneapolis, Minnesota.
Attallah, A.M.; Shiha, G.E.; Omran, M.M. and Zalata, K.R. (2006): A discriminant score based on four routine laboratory blood tests for accurate diagnosis of severe fibrosis and/or liver cirrhosis in Egyptian patients with chronic hepatitis C. Hepatology Research, 34(3): 163.
Attia, H.A.M.; Zekri, A.N.; Goudsmit, J.; Boom, R.; Khaled, H.M.; Mansour, M.T.; Dewaf, F.; Alam El-Din, H.M. and Sol, C.J.A. (1996): Diverse patterns of recognition of hepatitis C core and nonstructural antigens by antibodies present in Egyptian cancer patients and blood donors. Journal of Clinical Microbiology, 34(11): 2665.
Bacon, B.R. (2004): Chronic hepatitis C and normal ALT: Considerations for treatment. American Journal of Gastroenterology, 99(9): 1706.
Barjon, C.; Dahlqvist, G.; Calmus, Y. and Conti, F. (2015): Role of regulatory T-cells during hepatitis C infection: From the acute phase to post-transplantation. Digestive and Liver Disease, 47(11): 913.
Baskic, D.; Vukovic, V.R.; Popovic, S.; Djurdjevic, P.; Zaric, M.; Nikolic, I.; Zelen, I.; Mitrovic, M.; Avramovic, D. and Mijailovic, Z. (2017): Cytokine profile in chronic hepatitis C: An observation. Cytokine, 96: 185.
Bauer, J.D. (1982): Clinical Laboratory Methods. 9th ed. C.V. Mosby Co., USA, pp. 580.
Bengsch, B.; Thimme, R. and Blum, H.E. (2009): Role of host genetic factors in the outcome of hepatitis C virus infection. Viruses, 1(2): 104.
Bernard, A.; Brottier, P.; Georget, E.; Lepage, V. and Boumsell, L. (1984): Joint report of the first international workshop on human leukocyte differentiation antigens by investigators of the participating laboratories. In Leukocyte Typing I. Springer-Verlag, pp. 9–135.
Biasiolo, A.; Martini, A. and Pontisso, P. (2015): New biomarkers for clinical management of hepatitis C virus infected patients. World Journal of Clinical Infectious Diseases, 5(4): 59.
Bjero, K.; Skaug, K.; Haaland, T. and Freland, S.S. (1999): Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. QJM, 92: 433.
Bonilla, N.; Barget, N.; Andrieu, M.; Roulot, D.; Letoumelin, P.; Grando, V.; Trinchet, J.C.; Ganne-Carrie, N.; Beaugrand, M.; Deny, P.; Choppin, J.; Guillet, J. and Ziol, M. (2006): Interferon gamma-secreting HCV-specific CD8+ T cells in the liver of patients with chronic hepatitis C: Relation to liver fibrosis—ANRS HC EP07 study. Journal of Viral Hepatitis, 13(7): 474.
Booth, J.C.; Kumar, U.; Webster, D.; Monjardino, J. and Thomas, H.C. (1998): Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology, 27: 223.
Caini, P.; Guerra, C.T.; Giannini, C.; Giannelli, F.; Gragnani, L.; Petrarca, A.; Solazzo, V.; Monti, M.; Laffi, G. and Zignego, A.L. (2007): Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis, 14(1): 22.
Cardoso, E.M.; Duarte, M.A.; Ribeiro, E.; Rodrigues, P.; Hultcrantz, R.; Sampaio, P.; Ehrlich, R.; Carvalho, J.; Fraga, J. and de Sousa, M.A. (2004): Study of some hepatic immunological markers, iron load and virus genotype in chronic hepatitis C. Journal of Hepatology, 41(2): 319.
Cashman, S.B.; Marsden, B.D. and Dustin, L.B. (2014): The humoral and immune response to HCV: Understanding is key to vaccine development. Frontiers in Immunology, 5: 550.
Chapel, H.M.; Christie, J.M.L.; Peach, V. and Chapman, R.W.G. (2001): Five-years follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clinical Immunology, 99(3): 320.
Conte, V.P. (2000): Chronic viral hepatitis C. Part 1. General considerations. Arquivos de Gastroenterologia, 37(3): 187.
Cribier, B.; Schmitt, C.; Rey, D.; Lang, J.M.; Kim, A. and Stoll-Keller, F. (1998): Production of cytokines in patients infected by hepatitis C virus. Journal of Medical Virology, 55: 89.
Crispe, I.N. (1999): How is the liver unique? In T lymphocytes in the liver: Immunobiology, pathology, and host defense. Wiley-Liss.
De Gaulle, I.; Loonawat, C.R.; Sehgal, M.; Patel, D. and Jain, P. (2019): Hepatitis C virus infection: Host-virus interaction and mechanisms of viral persistence. Cells, 8(4): 376.
De Groote, D.; Marchant, A.; Fauchet, F.; Jadoul, M.; Dehart, I.; Gerard, C.; Gevaert, Y.; Lopez, M.; Gathy, R. and Franssen, J.D. (1994): Characterization of monoclonal antibodies against human interleukin-10 and their use in an ELISA for the measurement of this cytokine. Journal of Immunological Methods, 177: 225.
Dimitropoulou, D.; Karakantza, M.; Tsamandas, A.C.; Mouzaki, A.; Theodorou, G. and Gogos, C.A. (2011): T-lymphocyte subsets in peripheral blood and liver tissue of patients with chronic B and C hepatitis. In Vivo, 25(6): 841.
Doumas, B.T.; Watson, W.A. and Homer, C.B. (1971): Albumin standards and the measurements of serum albumin with bromocresol green. Clinica Chimica Acta, 31: 87.
Dustin, L.B. (2017): Innate and adaptive immune responses in chronic HCV infection. Current Drug Targets, 18(7): 826.
El-Sherif, M.; Mansy, H.; El-Dusari, S. and Faqeeh, M. (2003): Schistosomiasis as a possible risk factor for acquiring hepatitis C virus (HCV) infection among Saudis. Saudi Medical Journal, 24(2): 143.
El Bassat, H.; Abo Alim, L.; Alam El-Din, R.A.; Hasby, E. and Shabah, A. (2013): Serum level of interleukin-10 with its gene polymorphism can be predictor of response to treatment in Egyptian patients with chronic hepatitis C virus. Egyptian Journal of Medical Human Genetics, 14(3): 227.
El-Ghitany, E.M. and Farghaly, A.G. (2019): Geospatial epidemiology of hepatitis C infection in Egypt by governorate. Heliyon, 5(8): e02249.
Eminler, A.T.; Ayyildiz, T.; Irak, K. and Kiyici, M. (2015): AST/ALT ratio is not useful in predicting the degree of fibrosis in chronic viral hepatitis patients. European Journal of Gastroenterology & Hepatology, 27(12): 1361.
Estakhri, R.; Somi, M.H.; Taban Sadeghi, A.; Hajipour, B. and Tajallayi, F. (2012): Evaluation of correlation between serum immunoglobulin levels and extent of hepatic fibrosis in patients with chronic B hepatitis. Life Science Journal, 9(4): 2969.
Falasca, K.; Ucciferri, C.; Dalessandro, M.; Zingariello, P.; Mancino, P.; Petrarca, C.; Pizzigallo, E.; Conti, P. and Vecchiet, J. (2006): Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Annals of Clinical & Laboratory Science, 36(2): 144.
Fallahi, P.; Ferri, C.; Ferrari, S.M.; Corrado, A.; Sansonno, D. and Antonelli, A. (2012): Cytokines and HCV-related disorders. Clinical and Developmental Immunology, Article ID 468107.
Fallatah, H.I. and Akbar, H.O. (2010): Elevated serum immunoglobulin G levels in patients with chronic liver disease in comparison to patients with autoimmune hepatitis. Libyan Journal of Medicine, 5: 10.
Fan, X.; Liu, W. and Li, C. (2000): Determination of serum cytokines in individuals with HCV infection. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 14(2): 145.
Fernandez-Checa, J.E. (2003): Alcohol-induced liver disease: When fat and oxidative stress meet. Annals of Hepatology, 2(2): 69.
Freeman, A.; Pan, Y.; Harvey, C.E.; Post, J.; Law, M.G.; White, P.A.; Rawlinson, W.D.; Lloyd, A.R.; Marinos, G. and Ffrench, R.A. (2003): The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. Journal of Hepatology, 38(3): 349.
Freeman, A.J.; Ffrench, R.A.; Post, J.T.; Harvey, C.E.; Gilmour, S.J.; White, P.A.; Marinos, G.; van Beek, I.; Rawlinson, W.D. and Lloyd, A.R. (2004): Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. Journal of Infectious Diseases, 190(6): 1093.
Fuller, M.J. and Zajac, A.J. (2003): Ablation of CD8 and CD4 T-cell responses by high viral loads. Journal of Immunology, 170: 477.
Gad, Y.Z.; Mouas, N.; Abdel-Aziz, A.; Abousmra, N. and Elhadidy, M. (2012): Distinct immunoregulatory cytokine pattern in Egyptian patients with occult hepatitis C infection and unexplained persistently elevated liver transaminases. Asian Journal of Transfusion Science, 6(1): 24.
Garcia-Suarez, J.; Burgaleta, C.; Hernanz, N.; Albarran, F.; Tobaruela, P. and Alvarez-Mon, M. (2000): HCV-associated thrombocytopenia: Clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. British Journal of Haematology, 110(1): 98.
Giannini, E.; Risso, D.; Botta, F.; Chiarbonello, B.; Fasoli, A.; Malfatti, F.; Romagnoli, P.; Testa, E.; Ceppa, P. and Testa, R. (2003): Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Archives of Internal Medicine, 163(2): 218.
Giboney, P.T. (2005): Mildly elevated liver transaminase levels in the asymptomatic patient. American Family Physician, 71(6): 1105.
Grau, G.E.; Roux-Lombard, P.; Gysler, C.; Lambert, C.; Lambert, P.H.; Dayer, J.M. and Guillevin, L. (1989): Serum cytokine changes in systemic vasculitis. Immunology, 68: 196.
Haroun, M. (2005): Effect of anti-immunoglobulin antibodies provides new insights into immune response to HCV. Journal of Medical Investigation, 52(3–4): 172.
Heim, M.H. and Thimme, R. (2014): Innate and adaptive immune responses in HCV infections. Journal of Hepatology, 61: S14.
Hiraga, N.; Suzuki, F.; Akuta, N.; Suzuki, Y.; Sezaki, H.; Hosaka, T.; Someya, T.; Kobayashi, M.; Saitoh, S.; Arase, Y.; Ikeda, K.; Kobayashi, M.; Matsuda, M.; Watabiki, S.; Satoh, J. and Kumada, H. (2005): Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up. Journal of Medical Virology, 75: 240.
Holmberg, S.D.; Lu, M.; Rupp, L.B.; Lamerato, L.E.; Moorman, A.C.; Vijayadeva, V.; Boscarino, J.A.; Henkle, E.M. and Gordon, S.C. (2013): Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clinical Infectious Diseases, 57(2): 240.
Hoshida, Y.; Fuchs, B.C.; Bardeesy, N.; Baumert, T.F. and Chung, R.T. (2014): Pathogenesis and prevention of hepatitis virus-induced hepatocellular carcinoma. Journal of Hepatology, 61: 579.
Huang, Y.; Yang, H.; Borg, B.B.; Su, X.; Rhodes, S.L.; Yang, K.; Tong, X.; Tang, G.; Howell, C.D.; Rosen, H.R.; Thio, C.L.; Thomas, D.L.; Alter, H.J.; Sapp, R.K. and Liang, T.J. (2007): A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proceedings of the National Academy of Sciences USA, 104(3): 985.
Humthip, K. and Maneekarn, N. (2015): The role of HCV proteins on treatment outcomes. Virology Journal, 12: 217.
Hustead, R.T.R. (2011): Causes and evaluation of mildly elevated liver transaminase levels. American Family Physician, 48(a): 1003.
Itakura, J.; Nagayama, K.; Enomoto, N.; Hamano, K.; Sakamoto, N.; Fanning, L.J.; Kenny-Walsh, E.; Shanahan, F. and Watanabe, M. (2005): Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin. Journal of Viral Hepatitis, 12(6): 594.
Ivanov, A.V.; Bartosch, B.; Smirnova, O.; Isaguliants, A. and Kochetkov, S.N. (2013): HCV and oxidative stress in the liver. Viruses, 5(2): 439.
Ivanov, A.V.; Valuev-Elliston, V.T.; Tyurina, D.A.; Ivanova, O.N.; Kochetkov, S.N.; Bartosch, B. and Isaguliants, M.G. (2017): Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis. Oncotarget, 8(3): 3895.
Jorgensen, B.; Fischer, E.; Ingeberg, S.; Hollaender, N.; Ring-Larsen, H. and Henriksen, J.H. (1984): Decreased blood platelet volume and count in patients with liver disease. Scandinavian Journal of Gastroenterology, 19(4): 492–496.
Kang, J. and Lee, M. (2017): Noninvasive diagnostic and prognostic assessment tools for liver fibrosis and cirrhosis in patients with chronic liver disease. In Liver Cirrhosis: Update and Current Challenges (Ed. Georgios Tsoulfas).
Khan, S.T.; Karges, W.; Cooper, C.L. and Crowe, A.M. (2018): Hepatitis C virus core protein reduces CD8+ T-cell proliferation, perforin production and degranulation but increases STAT5 activation. Immunology, 154(1): 156.
Khokhar, N. (2003): Serum aminotransferase levels and platelet count as predictive factors of fibrosis and cirrhosis in patients with chronic hepatitis C infection. Journal of the Pakistan Medical Association, 53(3): 101–104.
Kirmaz, C.; Terzioglu, E.; Topalak, O.; Bayrak, P.; Yilmaz, O.; Ersoz, G. and Sebik, F. (2004): Serum transforming growth factor-beta (TGF-beta1) in patients with cirrhosis, chronic hepatitis B and chronic hepatitis C. European Cytokine Network, 15(2): 112.
Kobayashi, K.; Ishii, M.; Shiina, M.; Ueno, Y.; Kondo, Y.; Kanno, A.; Miyazaki, Y.; Yamamoto, T.; Kobayashi, T.; Niitsuma, H.; Kikumoto, Y.; Takizawa, H. and Shimosegawa, T. (2005): Interferon-gamma is produced by CD8 T cells in response to HLA-A24-restricted hepatitis C virus epitopes after sustained virus loss. Clinical and Experimental Immunology, 141(1): 81.
Kurachi, M. (2019): CD8+ T-cell exhaustion. Seminars in Immunopathology, 41: 327.
Lackner, C.; Struber, G.; Liegl, B.; Leibl, S.; Ofner, P.; Bankuti, C.; Bauer, B. and Stauber, R.E. (2005): Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology, 41: 1376.
Lecour, S.; Rochette, L. and Opie, L. (2005): Free radicals trigger TNF-alpha-induced cardioprotection. Cardiovascular Research, 65(1): 239.
Leroux-Roels, G.; Offner, F.; Philippe, J. and Vermeulen, A. (1988): Influence of blood-collecting systems on concentrations of tumor necrosis factor in serum and plasma. Clinical Chemistry, 34: 2373.
Li, H.; Huang, M.; Jiang, J. and Peng, Z. (2018): Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. World Journal of Gastroenterology, 24(47): 5297.
Lichterfeld, M.; Leifeld, L.; Nischalke, H.D.; Rockstroh, J.K.; He, B.L.; Sauerbruch, T. and Spengler, U. (2002): Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. Journal of Infectious Diseases, 185: 1803.
Lin, S.; Sun, Q.Q.; Mao, W. and Chen, Y. (2016): Serum immunoglobulin A (IgA) level is a potential biomarker indicating cirrhosis during chronic hepatitis B infection. Gastroenterology Research and Practice, Article ID 2495073.
Liu, C.; Zhu, H.; Tu, Z.; Xu, Y.L. and Nelson, D.R. (2003b): CD8 T-cell interaction with HCV replicon cells: Evidence for both cytokine- and cell-mediated antiviral activity. Hepatology, 37: 1335.
Liu, X.D.; Wu, J.L.; Liang, J.; Zhang, T. and Sheng, Q.S. (2012): Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus-infected patients. World Journal of Gastroenterology, 18(22): 2784.
Lotfy, M.; El-Kady, I.M.; Nasif, W.A.; El-Kenawy, A.E. and Badra, G. (2006): Distinct serum immunoglobulins pattern in Egyptian patients with chronic HCV infection analyzed by nephelometry. Journal of Immunoassay and Immunochemistry, 27(1): 103.
Lucas, M.; Vargas-Cuero, A.L. and Lauer, G.M. (2004): Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8 T cells. Journal of Immunology, 172: 1744.
Luik, A.; Knapp, S.; Thursz, M.; Thomas, H.C. and Schlaak, J.F. (2004): Autoregulatory role of interleukin-10 in hepatitis C patients treated with IFN-alpha. Journal of Interferon and Cytokine Research, 24(10): 585.
Mally, H.T. and Evelyn, K.A. (1937): The determination of bilirubin with the photoelectric colorimetric method. Journal of Biological Chemistry, 119: 481.
Mansy, H.; El-Sherif, M.; El-Dusari, M.S. and Faqeeh, M. (2003): Hemodialysis patients with hepatitis C: Should they be considered for renal transplant? Saudi Medical Journal, 2: S127.
Marin-Serrano, E.; Rodriguez-Ramos, C.; Diaz, F.; Martin-Herrera, L. and Giron-Gonzalez, J.A. (2006): Modulation of the anti-inflammatory interleukin-10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. Journal of Viral Hepatitis, 13(4): 230.
Maruyama, S.; Hirayama, C.; Horie, Y.; Yorozu, K.; Maeda, K.; Inoue, M.; Fujii, Y.; Umeki, K. and Koda, M. (2007): Serum immunoglobulins in patients with chronic hepatitis C: A surrogate marker of disease severity and treatment outcome. Hepatogastroenterology, 54(74): 493.
Mateescu, R.B.; Rimbas, M. and Voiosu, R. (2004): The immunopathogenesis of viral hepatitis. Romanian Journal of Internal Medicine, 42(1): 59.
Maylin, S.; Laouénan, C.; Martinot-Peignoux, M.; Panhard, X.; Lapalus, M.; Nicolas-Chanoine, M.H.; Bedossa, P.; Asselah, T. and Marcellin, P. (2012): Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy. Journal of Clinical Virology, 53(1): 43.
McPherson, S.; Henderson, E.; Burt, A.D.; Day, C.P. and Anstee, Q.M. (2014): Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. Hepatology, 60(5): 1055.
Miller, J.B.; Figeraa, E.J.; Haug, R.M. and Shah, N.L. (2019): Thrombocytopenia in chronic disease and the role of thrombopoietin agonists. Gastroenterology & Hepatology, 15(6): 326.
Miossec, P.; Naviliat, M.; Dupuy, d’A.A.; Sany, J. and Banchereau, J. (1990): Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis & Rheumatism, 33(8): 1180.
Mishra, P.K.; Bhargava, A.; Vashistha, P.; Varshney, S. and Maudar, K.K. (2010): Mediators of the immune system and their possible role in pathogenesis of chronic hepatitis B and C viral infections. AsPac Journal of Molecular Biology and Biotechnology, 18(3): 341.
Momran, M.; Frid, K.; Emran, T.M. and Attallah, A.A. (2011): Fibro-α score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C virus patients. Arab Journal of Gastroenterology, 2: 74.
Morishima, I.; Kumada, T.; Nakano, S.; Takeda, I.; Sugiyama, K.; Osada, T.; Kiriyama, S.; Ohki, H.; Suga, T. and Ito, O. (1995): Serum levels of soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alpha. Scandinavian Journal of Gastroenterology, 30(8): 807.
Mourtzikou, A.; Alepakia, M.; Stamoulic, M.; Pouliakisa, A.; Sklirisc, A. and Karakitsosa, P. (2014): Evaluation of serum levels of IL-6, TNF-α, IL-10, IL-2 and IL-4 in patients with chronic hepatitis. Immunologia, 33(1): 41.
Mourtzikou, A.; Alepakia, M.; Stamoulic, M.; Pouliakisa, A.; Skliris, A. and Karakitsosa, P. (2014): Evaluation of serum levels of IL-6, TNF-α, IL-10, IL-2 and IL-4 in patients with chronic hepatitis. Immunologia, 33(2): 41.
Murawaki, Y.; Ikuta, Y.; Koda, M. and Kawasaki, H. (2001): Comparison of clinical laboratory liver tests between asymptomatic HBV and HCV carriers with persistently normal aminotransferase serum levels. Hepatology Research, (1): 67.
Murray, H.W. (1988): Interferon gamma, the activated macrophage and host defense against microbial challenge. Annals of Internal Medicine, 108: 595.
Nisii, C.; Tempestilli, M.; Agrati, C.; Poccia, F.; Tocci, G.; Longo, M.A.; D’Offizi, G.; Tersigni, R.; Lo Iacono, O.; Antonucci, G. and Oliva, A. (2006): Accumulation of dysfunctional effector CD8+ T cells in the liver of patients with chronic HCV infection. Journal of Hepatology, 44(3): 475.
Njiomegnie, G.F.; Read, S.A.; Fewings, N.; George, J.; McKay, F. and Ahlenstiel, G. (2020): Immunomodulation of the natural killer cell phenotype and response during HCV infection. Journal of Clinical Medicine, 9(4): 1030.
Nuti, R.; Brandi, M.L.; Checchia, G.; Di Munno, O.; Dominguez, L.; Falaschi, P.; Fiore, C.E.; Lolascon, G.; Mahhi, S. and Michieli, R. (2019): Guidelines for the management of osteoporosis and fragility fractures. Internal and Emergency Medicine, 14: 85.
Ortarik, Z.; Toyran, A.; Sen, S.; Mart Kömürcü, S.Z. and Güvener, E. (2011): Evaluation of serum IgG, IgA and IgM levels as indicators of hepatic fibrosis in patients with chronic hepatitis B infection. Mikrobiyoloji Bülteni, 45(2): 296.
Ortarik, Z.; Toyran, A.; Sen, S.; Mart Kömürcü, S.Z. and Güvener, E. (2011): Evaluation of serum IgG, IgA and IgM levels as indicators of hepatic fibrosis in patients with chronic hepatitis C infection. Mikrobiyoloji Bülteni, 45(2): 296.
Paolicchi, A.; Marchi, S.; Petruccelli, S.; Ciancia, E.; Molvaldi, G. and Pompella, A. (2005): Gamma-glutamyltransferase in fine-needle liver biopsies of subjects with chronic hepatitis C. Journal of Viral Hepatitis, 12(3): 269.
Perrella, A.; Borgia, G. and Perrella, O. (2004): Immune system homeostasis during acute hepatitis C: Viral escape or T-cell regulation? Hepatology, 40(5): 1229.
Persijn, J.P.U. and Van der Slik, W. (1976): A new method for the determination of gamma-glutamyltransferase in serum. Journal of Clinical Chemistry and Clinical Biochemistry, 14(9): 421.
Porto-Espinoza, L.; Cuadra-Sanchez, C.; Moronta, R.; Monsalye-Castillo, F. and Callejas-Valero, D. (2006): Immune evasion mechanisms of hepatitis C virus. Investigacion Clinica, 47(1): 71.
Post, J.J.; Pan, Y.; Freeman, A.J.; Harvey, C.E.; White, P.A.; Palladinetti, P.; Haber, P.S.; Marinos, G.; Levy, M.H.; Kaldor, J.M.; Dolan, K.A.; Ffrench, R.A.; Lloyd, A.R. and Rawlinson, W.D. (2004): Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. Journal of Infectious Diseases, 189(10): 1846.
Pugliese, A.; Gennero, L.; Cutufia, M.; Enrietto, M.; Morra, E.; Pescarmona, P. and Ponzetto, A. (2004): HCV infective virions can be carried by human platelets. Cell Biochemistry and Function, 22: 353.
Rajan, S.K.; Espina, B.M. and Liebman, H.A. (2005): Hepatitis C virus-related thrombocytopenia: Clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. British Journal of Haematology, 129(6): 818.
Ramadori, P.; Klag, T.; Lalek, N.P. and Heikenwalder, M. (2019): Platelets in chronic liver disease from bench to bedside. JHEP Reports, 1(6): 448.
Ramos, J.A.; Silva, R.; Hoffmann, L.; Ramos, A.L.; Cabello, P.H.; Urményi, T.P.; Villella-Nogueira, C.A.; Lewis-Ximenez, L. and Rondinelli, E. (2012): Association of IL-10, IL-4 and IL-28B gene polymorphisms with spontaneous clearance of hepatitis C virus in a population from Rio de Janeiro. BMC Research Notes, 5: 508.
Rehermann, B. (2000): Interaction between the hepatitis C virus and the immune system. Seminars in Liver Disease, 20: 127.
Reitman, S. and Frankel, S. (1957): A colorimetric method for the determination of serum glutamic oxaloacetic acid and glutamic pyruvic transaminases. American Journal of Clinical Pathology, 28: 56.
Rothman, A.L.; Morishima, C.; Bonkovsky, H.L.; Polyak, S.J.; Ray, R.; Di Bisceglie, A.M.; Lindsay, K.L.; Malet, P.F.; Chang, M.; Gretch, D.R.; Sullivan, D.G.; Bhan, A.K.; Wright, E.C.; Koziel, M.J. and HALT-C Trial Group. (2005): Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology, 41(3): 617.
Roughan, J.E.; Reardon, K.M.; Cogburn, K.E.; Quendler, H.; Pockros, P.J. and Law, M. (2012): Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. Clinical and Vaccine Immunology, 19(7): 1027.
R-Viso, A.T.; Duarte, M.I.S.; Pagliari, C.; Fernandes, E.R.; Brasil, R.A.; Benard, G.; Romano, C.C.; Ogusuku, S.; Cavalheiro, N.P.; Melo, C.E. and Barone, A.A. (2010): Tissue and serum immune response in chronic hepatitis C with mild histological lesions. Memórias do Instituto Oswaldo Cruz, 105(1): 25.
Saad, E.A. (2014): Non-invasive assessment of liver fibrosis using serum markers. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 2(2): 59.
Sachiyo, Y. and Tatsuya, K. (2016): Host-virus interactions in hepatitis B and hepatitis C infection. Journal of Gastroenterology, 51: 409.
Schirren, C.A.; Jung, M.C.; Gerlach, J.T.; Worzfeld, T.; Baretton, G.; Mamin, M.; Hubert, Gruener, N.; Houghton, M. and Pape, G.R. (2000): Liver-derived hepatitis C virus-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma. Hepatology, 32(3): 597.
Schrier, S.B.; Hill, A.S.; Plana, D. and Lauffenburger, D.A. (2016): Synergistic communication between CD4+ T cells and monocytes impacts the cytokine environment. Scientific Reports, 6: 34942.
Semmon, G.; Krashias, C. and Klenerman, W.P. (2007): Analysis of the relationship between cytokine secretion and proliferative capacity in hepatitis C virus infection. Journal of Viral Hepatitis, 14: 7.
Shen, H.; Huang, G.; Zhang, M.; Kaita, K.; Minuk, G. and Gong, Y. (2001): Effects of immunoglobulin G on the proliferation and activation of subcultured rat hepatic stellate cells. Hepatology, 34: 403.
Sherman, K.E.; Rouster, S.D.; Chung, R.T. and Rajicic, N. (2002): Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS clinical trial group. Clinical Infectious Diseases, 34: 831.
Sheth, S.G.; Flamm, S.L.; Gordon, F.D. and Chopra, S. (1998): AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. American Journal of Gastroenterology, 93(1): 44.
Shoukry, N.H.; Grakoui, A.; Houghton, M.; Chien, D.Y.; Ghrayeb, J.; Reimann, K.A. and Walker, C.M. (2003): Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. Journal of Experimental Medicine, 197(12): 1645.
Sobchak, D.M. and Korochkina, O.V. (2005): Cytokine regulation of immune response in patients with acute HCV infection. Terapevticheskii Arkhiv, 77(11): 23.
Spanakis, N.E.; Garinis, G.A.; Alexopoulos, E.C.; Patrinos, G.P.; Menounos, P.G.; Sklavounou, A.; Manolis, E.N.; Gorgoulis, V.G. and Valis, D. (2002): Cytokine serum levels in patients with chronic HCV infection. Journal of Clinical Laboratory Analysis, 16: 40.
Spieki, N.; Antal-Szalmas, P.; Lakatos, P.L. and Papp, M. (2014): Immune dysfunction in cirrhosis. World Journal of Gastroenterology, 20: 2564.
Sullivan, T. (2016): The implication of low absolute CD4+ counts in patients with cirrhosis and human immunodeficiency virus. Open Forum Infectious Diseases, 3(2): ofw060.
Taliani, G.; Badolato, M.C.; Nigro, G.; Biasin, M.; Boddi, V.; Pasquazzi, C. and Clerici, M. (2002): Serum concentration of gamma GT is a surrogate marker of hepatic TNF-alpha mRNA expression in chronic hepatitis C. Clinical Immunology, 105(3): 279.
Taylor, E.R.; Hurrell, F.; Shannon, R.J.; Lin, T.K.; Hirst, J. and Murphy, M.P. (2003): Reversible glutathionylation of complex I increases mitochondrial superoxide formation. Journal of Biological Chemistry, 278(22): 19603.
Terilli, R.R. and Cox, A.L. (2014): Immunity and hepatitis C: A review. Current HIV/AIDS Reports, 10(1): 51.
Thimme, R.; Binder, M. and Bartenschlager, R. (2012): Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiology Reviews, 36(3): 663.
Thimme, R.; Lohmann, V. and Weber, F. (2006): A target on the move: Innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Research, 69(3): 129.
Tisone, G.; Orlando, G.; Cardillo, A.; Palmieri, G.; Manzia, T.M.; Baiocchi, L.; Lionetti, R.; Anselmo, A.; Toti, L. and Angelico, M. (2006): Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. Journal of Hepatology, 44(4): 702–709.
Umemura, T.; Wang, R.Y.; Schechterly, C.; Shih, J.W.; Kiyosawa, K. and Alter, H.J. (2006): Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology, 43(1): 91.
Urbani, S.; Amadei, B.; Fisicaro, P.; Pilli, M.; Missale, G.; Bertoletti, A. and Ferrari, C. (2005b): Heterologous T-cell immunity in severe hepatitis C virus infection. Journal of Experimental Medicine, 201(5): 675.
Urbanowicz, A.; Zagożdżon, R. and Ciszek, M. (2019): Modulation of the immune system in chronic hepatitis C and during antiviral interferon-free therapy. Archivum Immunologiae et Therapiae Experimentalis, 67(2): 79.
Valva, P.; Rios, D.A.; De Matteo, E. and Preciado, M.V. (2016): Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World Journal of Gastroenterology, 22(4): 1367.
Varano, B.; Fantuzzi, L.; Puddu, P.; Borghi, P.; Belardelli, F. and Gessani, S. (2000): Inhibition of the constitutive and induced IFN-beta production by IL-4 and IL-10 in murine peritoneal macrophages. Virology, 277(2): 270.
Vince, A. (2005): Hepatitis B and C: Natural course of disease. Acta Medica Croatica, 59(5): 389.
Wai, C.T.; Greenson, J.K.; Fontana, R.J.; Kalbfleisch, J.D.; Marrero, J.A.; Conjeevaram, H.S. and Lok, A.S. (2003): A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 38: 518.
Wand, H.; Peng, C.; Lai, H.; Su, W.; Lin, C.; Chuang, P.; Chen, S.; Chen, C.; Hsu, W. and Huang, G. (2017): Invasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis. Scientific Reports, 7(1): 3259.
Wang, K.; Wu, Z.B.; Ye, Y.N.; Liu, J.; Zhang, G.L.; Su, Y.J.; He, H.L.; Zheng, Y.B. and Gao, Z.L. (2014): Plasma interleukin-10: A likely predictive marker for hepatitis B virus-related acute-on-chronic liver failure. Hepatitis Monthly, 14(7): e19370.
Wang, Q.C.; Feng, Z.H.; Zhou, Y.X. and Nie, Q.H. (2005): Induction of hepatitis C virus-specific cytotoxic T and B cell responses by dendritic cells expressing a modified antigen targeting receptor. World Journal of Gastroenterology, 11(4): 557.
Wang, Y.; Kato, N.; Jazag, D.N.; Otsuka, M.; Taniguchi, H.; Kawabe, T. and Omata, M. (2006): Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology, 130(3): 883.
Watson, M.W.; Jaksic, A.; Price, P.; Cheng, W.; McInerney, M.; French, M.A.; Fisher, S.; Lee, S. and Flexman, J.P. (2003): Interferon-gamma response by peripheral blood mononuclear cells to hepatitis C virus core antigen is reduced in patients with liver fibrosis. Journal of Infectious Diseases, 188(10): 1533.
Watt, K.; Uhanova, J.; Gong, Y.; Kaita, K.; Doucette, K.; Pettigrew, N. and Minuk, G.Y. (2004): Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis, 11(3): 251.
Weichselbaum, T.E. (1946): An accurate and rapid method for determination of proteins in small amounts of blood serum and plasma. American Journal of Clinical Pathology, 16: 40.
West, A.P.; Shadel, G.S. and Ghosh, S. (2011): Mitochondria in innate immune responses. Nature Reviews Immunology, 11: 389.
Whicher, J.T.; Price, C.P. and Spencer, K. (1983): Immunonephelometric and immunoturbidimetric assays for proteins. Critical Reviews in Clinical Laboratory Sciences, 18(3): 213.
Xu, R.; Zhang, Z. and Wang, F. (2012): Liver fibrosis: Mechanisms of immune-mediated liver injury. Cellular & Molecular Immunology, 9(4): 296.
Yan, Z. and Wang, Y. (2017): Viral and host factors associated with outcomes of hepatitis C virus infection. Molecular Medicine Reports, 15(5): 2909.
Yilmaz, Y.; Yonal, O.; Kurt, R.; Bayrak, M.; Aktas, B. and Ozdogen, O. (2011): Non-invasive assessment of liver fibrosis with aspartate aminotransferase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease. Hepatology, 11(2): 103.
Yokoyama, A.; Kohno, N.; Fujino, S.; Inoue, Y. and Hiwada, K. (1995): IgG and IgM rheumatoid factor levels parallel interleukin-6 during the vasculitic phase in a patient with Churg-Strauss syndrome. Internal Medicine, 34(7): 646.
Yumoto, E.; Higashi, T.; Nouso, K.; Nakatsukass, H.; Rujiwara, K.; Hanafusa, T.; Yumoto, Y.; Tanimoto, Y.; Kurimoto, M.; Tanaka, N. and Tsuji, T. (2002): Serum gamma-interferon inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. Journal of Gastroenterology and Hepatology, 17(3): 285.
Zampino, R.; Marrone, A.; Restivo, L.; Guerrera, B.; Sellitto, A.; Rinaldi, L.; Romano, C. and Adinolfi, L.E. (2013): Chronic HCV infection and inflammation: Clinical impact on hepatic and extrahepatic manifestations. World Journal of Hepatology, 5(10): 528.
Zechini, B.; Pasquazzi, C. and Aceti, A. (2004): Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: The role of serum aspartate transaminase in the evaluation of disease progression. European Journal of Gastroenterology & Hepatology, 16(9): 891.
Zhang, L.; Hao, C.Q.; Miao, L. and Dou, X. (2014): Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy. Genetics and Molecular Research, 13(4): 9747.
Zhang, L.; Miao, L.; Han, F. and Dou, X. (2011): Cytokine levels in serum of patients with chronic hepatitis C and its significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 27(3): 301.
Zhou, W.; Zhang, Q. and Qiao, L. (2014): Pathogenesis of liver cirrhosis. World Journal of Gastroenterology, 20(23): 7312.
Zimmerman, R.J.; Chan, A. and Leadon, S.A. (1989): Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Research, 49: 1644.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 N M Abdallah, R M Yousry , F F Abdel Hamid, M N EI- Rouby, S M Abdel Fattah (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
